{
  "id": 19800962,
  "title": "Immunic shares fall 5% on third quarter earnings miss",
  "url": "https://urgent.news/2026/11/13/immunic-shares-fall-5-on-third-quarter-earnings-miss",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-13T11:44:04.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/earnings/immunic-shares-fall-5-on-third-quarter-earnings-miss-5024923"
  },
  "original_language": "en",
  "account": "Immunic Inc. (IMUX) reported weaker-than-expected third-quarter earnings, resulting in a 5.44% drop in its shares in pre-market trading. The biotechnology company disclosed a net loss of $42.3 million, or -$0.99 per share, for the period ending September 30, 2026, which surpassed analyst predictions by $0.05. This decline in earnings was primarily attributed to increased personnel costs, drug supply expenses, and NDA readiness activities. The total operating expenses for the quarter rose to $43.4 million, up from $26.0 million a year prior.\n\nThe company's top-line data from their Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis remains on track for December 2026. CEO Erik Lundgren expressed confidence that Immunic is entering a critical phase in its history as the Phase 3 trial results draw nearer. However, the company's financial situation is complicated by a significant surge in general and administrative expenses, which increased to $19.4 million, primarily due to an $11.0 million rise in personnel expenses. Specifically, $9.7 million of this increase was attributed to non-cash stock compensation from a separation agreement. Despite this, Immunic holds $132.0 million in cash and cash equivalents as of September 30, 2026, which it anticipates will sustain operations until late 2027.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}